Haemonetics (HAE) Financials, Dividends & Stock Info
Explore comprehensive financial data for Haemonetics, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (181 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
Haemonetics (HAE) is a health care supplies company. The company reports annual revenue of $1.4B and net income of $168M. Its profit margin is 12.3%.
Haemonetics Key Financials
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Haemonetics Financial Health ScoreFY2025
Moderate health; several metrics need attention
-8 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Mar 28, 2026
About Haemonetics
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
- Industry
- Health Care Supplies
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Positive Marginsvs 8.9% sector median / 2.3% avg
Keeps 12 cents of every dollar in revenue as profit. Higher than 82% in Health Care.
Profit margin 425% above sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Mar 28, 2026
Haemonetics 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $1.4B(+4.0%) | $1.3B(+12.0%) | $1.2B(+17.7%) | $993.2M | - | - | - | $225.4M(-74.6%) | $886.1M(-2.5%) |
| Net Income | - | $167.7M(+42.6%) | $117.6M(+1.9%) | $115.4M(+166.1%) | $43.4M(-45.4%) | $79.5M(+3.8%) | $76.5M(+39.1%) | $55.0M(+20.7%) | $45.6M(+273.5%) | $-26,268,000(+52.7%) |
| Total Assets | $2.5B | $2.2B | $1.9B | $1.9B | $1.8B | $1.3B | $1.3B | $1.2B | $1.2B | $1.3B |
| Total Debt | $1.2B | $797.6M | $754.1M | $559.4M | $690.6M | $305.5M | $322.5M | $59.4M | $315.8M | $408.5M |
| Total Equity | $820.8M | $960.0M | $818.0M | $749.4M | $731.7M | $587.1M | $667.9M | $752.4M | $739.6M | $721.6M |
| Profit Margin | - | 12.3% | 9.0% | 9.9% | 4.4% | - | - | - | 20.2% | -3.0% |
| ROE | - | 17.5% | 14.4% | 15.4% | 5.9% | 13.5% | 11.5% | 7.3% | 6.2% | -3.6% |
| ROA | - | 7.6% | 6.1% | 6.2% | 2.4% | 6.3% | 6.0% | 4.5% | 3.7% | -2.0% |
Quarterly Financials
Last 8 quarters| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $327.3M | $321.4M | - | $345.5M | $336.2M | - | $318.2M | $311.3M |
| Net Income | $38.7M | $34.0M | - | $33.8M | $38.4M | - | $24.9M | $41.0M |
| Total Assets | $2.4B | $2.5B | $2.5B | $2.5B | $2.5B | - | $2.0B | $2.0B |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Haemonetics Free Cash Flow & Dividend Coverage
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | $159.7M | $220.3M | $159.3M | $158.2M | $108.8M | $172.3M | $273.1M | $181.8M | $181.7M | - |
| CapEx | -$76.1M | -$74.8M | -$119.0M | -$48.8M | -$37.0M | -$96.5M | -$191.3M | -$38.1M | -$39.3M | - |
| Free Cash Flow | $83.6M | $145.6M | $40.3M | $109.5M | $71.8M | $75.8M | $81.7M | $143.6M | $142.4M | - |
| FCF Margin | 9.4% | 64.6% | - | - | - | 7.6% | 7.0% | 11.0% | 10.5% | - |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Mar 28, 2026
Haemonetics Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for HAE.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Haemonetics FAQ
What is Haemonetics's annual revenue?
Haemonetics (HAE) reported $1.4 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Haemonetics profitable?
Yes, Haemonetics is profitable with a 12.3% net profit margin and $168 million in net income (TTM). All figures from SEC EDGAR 10-K filings.
Does Haemonetics pay dividends?
No, Haemonetics (HAE) does not currently pay dividends to shareholders.
What is Haemonetics's financial health score?
Haemonetics has a financial health score of 66/100 (Grade: C), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Haemonetics financial data are available?
10 years of financial data are available for Haemonetics from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.